EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

Renato Brito Baleeiro iD, Peng Liu, Louisa S Chard Dunmall, Carmela Di Gioia, Ai Nagano, Lauren Cutmore iD, Jun Wang, Claude Chelala, Lydon Wainaina Nyambura iD, Peter Walden, Nicholas Lemoine, Yaohe Wang iD

Journal for ImmunoTherapy of Cancer · 2023-08 · 11 (8) · e007336

DOI: 10.1136/jitc-2023-007336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 16.08.2023. Verfasst von Renato Brito Baleeiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers and Biotherapeutics, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Oncolytic Viruses. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple-negative breast cancer (TNBC) corresponds to approximately 20% of all breast tumors, with a high propensity for metastasis and a poor prognosis. Because TNBC displays a high mutational load compared with other breast cancer types, a neoantigen-based immunotherapy strategy could be effective. One major bottleneck in the development of a neoantigen-based vaccine for TNBC is the selection of the best targets, that is, tumor-specific neoantigens which are presented at the surface of tumor cells and capable of eliciting robust immune responses. In this study, we aimed to set up a platform for identification and delivery of immunogenic neoantigens in a vaccine regimen for TNBC using oncolytic vaccinia virus (VV).

Methods

We used bioinformatic tools and cell-based assays to identify immunogenic neoantigens in TNBC patients’ samples, human and murine cell lines. Immunogenicity of the neoantigens was tested in vitro (human) and ex vivo (murine) in T-cell assays. To assess the efficacy of our regimen, we used a preclinical model of TNBC where we treated tumor-bearing mice with neoantigens together with oncolytic VV and evaluated the effect on induction of neoantigen-specific CD8+T cells, tumor growth and survival.

Results

We successfully identified immunogenic neoantigens and generated neoantigen-specific CD8+T cells capable of recognizing a human TNBC cell line expressing the mutated gene. Using a preclinical model of TNBC, we showed that our tumor-specific oncolytic VV was able to change the tumor microenvironment, attracting and maintaining mature cross-presenting CD8α+dendritic cells and effector T-cells. Moreover, when delivered in a prime/boost regimen together with oncolytic VV, long peptides encompassing neoantigens were able to induce neoantigen-specific CD8+T cells, slow tumor growth and increase survival.

Conclusions

Our study provides a promising approach for the development of neoantigen-based immunotherapies for TNBC. By identifying immunogenic neoantigens and developing a delivery system through tumor-specific oncolytic VV, we have demonstrated that neoantigen-based vaccines could be effective in inducing neoantigen-specific CD8+T cells response with significant impact on tumor growth. Further studies are needed to determine the safety and efficacy of this approach in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsOncolytic VirusesHumansAnimalsMiceVaccinia virusBiological AssayCD8-Positive T-LymphocytesImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

Breast NeoplasmsImmunogenicity, VaccineImmunotherapyOncolytic Virotherapy

Autor:innen und Institutionen

  • Centre for Cancer Biomarkers and Biotherapeutics, Queen Mary University of London, London, UK.
  • Department of Dermatology, Venerology and Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Zhengzhou University, Zhengzhou, Henan, China.
  • Centre for Cancer Biomarkers and Biotherapeutics, Queen Mary University of London, London, UK yaohe.wang@qmul.ac.uk.

ORCID-Profile: Renato Brito Baleeiro, Lauren Cutmore, Lydon Wainaina Nyambura, Yaohe Wang

Förderung

  • Wellcome Trust
  • Medical Research Council
  • Cancer Research UK
  • Breast Cancer Now

Zitieren

APA

Brito Baleeiro, R., Liu, P., Chard Dunmall, L. S., Di Gioia, C., Nagano, A., Cutmore, L., Wang, J., Chelala, C., Nyambura, L. W., Walden, P., Lemoine, N., & Wang, Y. (2023). Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. Journal for ImmunoTherapy of Cancer, 11(8), e007336. https://doi.org/10.1136/jitc-2023-007336

Vancouver

Brito Baleeiro R, Liu P, Chard Dunmall LS, Di Gioia C, Nagano A, Cutmore L, et al. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2023;11(8):e007336. doi:10.1136/jitc-2023-007336

BibTeX
@article{BritoBaleeiro2023,
  author = {Brito Baleeiro, Renato and Liu, Peng and Chard Dunmall, Louisa S and Di Gioia, Carmela and Nagano, Ai and Cutmore, Lauren and Wang, Jun and Chelala, Claude and Nyambura, Lydon Wainaina and Walden, Peter and Lemoine, Nicholas and Wang, Yaohe},
  title = {Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {8},
  pages = {e007336},
  doi = {10.1136/jitc-2023-007336}
}
Kostenlos starten →